PRISM BioLab Co

PRISM BioLab Co Revenue per Employee

The Revenue per Employee of PRISM BioLab Co (206A.T) as of Nov 10, 2026 is 39.84 M JPY. In the previous year, Revenue per Employee was 17.98 M JPY — a change of 121.62% (higher).

Revenue per Employee

39.84 MJPY

YoY

121.62%

Last updated:

Revenue per Employee of PRISM BioLab Co is 2025 39.84 M JPY. Revenue per Employee of PRISM BioLab Co was 2024 17.98 M JPY. It decreases by 121.62% higher compared to the previous year.

The PRISM BioLab Co Revenue per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Employee
Date
Revenue per Employee
Jan 1, 2022
32.61 M JPY
Jan 1, 2023
6.64 M JPY
Jan 1, 2024
17.98 M JPY
Jan 1, 2025
39.84 M JPY
The PRISM BioLab Co Revenue per Employee history
YEARRevenue per EmployeeYoY
39.84 MJPY+121.62%
17.98 MJPY+170.64%
6.64 MJPY-79.63%
32.61 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PRISM BioLab Co Stock analysis

What does PRISM BioLab Co do? PRISM BioLab Co Ltd generates revenue through two distinct business models in the pharmaceuticals sector. The in-house development business focuses on selecting drug discovery targets and creating programs internally using their PepMetics technology platform. The joint development business collaborates with pharmaceutical companies to develop drug discovery programs leveraging their proprietary PepMetics technology. Both models utilize the company's owned drug discovery platform to create new pharmaceutical products. The company's primary clients are pharmaceutical companies seeking to develop new drugs through partnerships with PRISM BioLab's technology. PRISM BioLab's business model centers on its PepMetics technology, which serves as the foundation for both its in-house development and joint development segments. The company builds new drug discovery platforms and develops new drugs through these segments, targeting pharmaceutical companies as their main customers. The firm's research and development activities are conducted using their owned technology, which differentiates their approach in the drug discovery market. The company's revenue streams are derived from pharmaceutical companies that partner with PRISM BioLab for drug discovery programs. By utilizing their PepMetics technology platform, the company creates targeted drug discovery solutions that are developed either internally or in collaboration with pharmaceutical partners. This approach allows PRISM BioLab to generate income through both direct development efforts and collaborative projects with industry clients. PRISM BioLab Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PRISM BioLab Co stock

Revenue per Employee of PRISM BioLab Co is 39.84 M JPY in 2025.

Revenue per Employee of PRISM BioLab Co changed from 17.98 M JPY to 39.84 M JPY, representing a 121.62% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Revenue per Employee PRISM BioLab Co since 2006 – with annual values, charts, and detailed analysis.

Revenue per employee measures workforce productivity by dividing total revenue by the number of employees. Higher values indicate more efficient operations.

Revenue per Employee's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Revenue per Employee's PRISM BioLab Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — PRISM BioLab Co

All Key Metrics — PRISM BioLab Co